Will Johnson & Johnson say “Rybrevant”?
Johnson & Johnson said “Rybrevant” 7 times on its Oct 13, 2026 call (FY26 Q3), and on each of its last 8 calls: 9, 1, 8, 3, 3, 5, 5, 7 times. As of Oct 24, 2026, Johnson & Johnson said “Rybrevant” on 4 of 4 calls with a settled Kalshi or Polymarket mention market since Jan 21, 2026 (100%), most recently on Oct 13, 2026. Parrot’s p for the next listing is 93% (n=4, from settlement history blended with transcripts), not a forecast.
- Last 10
- 4/4Last 10 settled, oldest to newest: yes yes yes yes
- Streak
- said the last 4 times
- Counts
- company speakers + operator
- Market
- 89¢ Kalshi (may be delayed)
Where it was said
quotes of at most 25 words; select an appearance
Johnson & Johnson
Rybrevant
- Probability
- 93% · n=4
- Settled
- 4/4 (100%)
- Last calls
- said in 8 of 8
Next listing counts: company speakers + operator
Counts: company speakers + operator
7 counted (5 in prepared remarks, 2 in Q&A).
…early as the second line of treatment. In solid tumors, sales of RYBREVANT increased by 64%, reflecting its strength in lung cancer. By the end…
In lung cancer, RYBREVANT plus LAZCLUZE delivered growth of 63.5%, with strong share gains in the first and second lines driven by continued launch uptake…
Counts: company speakers + operator
5 counted (5 in prepared remarks, 0 in Q&A).
…pleased with the progress of our new launches, including ICOTYDE, INLEXZO, and RYBREVANT, instilling confidence that momentum will accelerate into 2027 and beyond, with line…
…In solid tumors, we continue to see strong performance from ERLEADA and RYBREVANT. We shared important new data for both at ASCO that could change…
Counts: company speakers + operator
5 counted (4 in prepared remarks, 1 in Q&A).
…potential new standard of care as early as second-line. In solid tumors, RYBREVANT FASPRO received FDA approval for subcutaneous monthly dosing for patients with EGFR-mutated…
Every settled listing
newest first · 5 shown
Kalshi
PolymarketQuestions
- How many times did Johnson & Johnson say “Rybrevant” on its last earnings call?
- Johnson & Johnson said “Rybrevant” 7 times on its Oct 13, 2026 call (FY26 Q3), and on each of its last 8 calls: 9, 1, 8, 3, 3, 5, 5, 7 times.
- How often does Johnson & Johnson say “Rybrevant”?
- As of Oct 24, 2026, Johnson & Johnson said “Rybrevant” on 4 of 4 calls with a settled Kalshi or Polymarket mention market since Jan 21, 2026 (100%), most recently on Oct 13, 2026.
- What is the probability Johnson & Johnson says “Rybrevant” next time?
- 93%, from settlement history blended with transcripts (n=4). It is a base rate from history, not a forecast and not advice.
- Who has to say it for the market to count?
- Under the next market's rule: company speakers + operator.
Cite parrot.markets, “Johnson & Johnson: ‘Rybrevant’ mention history”, as of Oct 24, 2026, https://parrot.markets/earnings/JNJ/words/rybrevant (CC BY 4.0)
Agents: this page as TSV at /api/v1/word?entity=johnson-and-johnson&word=rybrevant · quotes: /api/v1/quotes?entity=johnson-and-johnson&word=… · columnar JSON in #parrot-data · llms.txt · MCP